Precision biosciences stock.

Precision BioSciences to Present at Upcoming Sidoti Conference. DURHAM, N.C., November 10, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and …33,354.14. -0.10%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Precision BioSciences Inc (DTIL.O) real-time stock quotes, news, price and financial information from Reuters ...Dec 1, 2023 · 3 equities research analysts have issued 1 year price targets for Precision BioSciences' stock. Their DTIL share price targets range from $2.00 to $4.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 624.6% from the stock's current price. From Luke: Backing out its $160 million cash balance, Precision is valued at merely $130 million — a cheap valuation for a promising gene-editing company with proprietary tech and a big pharma ...

Jan 24, 2022 · This free interactive report on Precision BioSciences' balance sheet strength is a great place to start, if you want to investigate the stock further. A Different Perspective. Given that the market gained 5.6% in the last year, Precision BioSciences shareholders might be miffed that they lost 65%. On November 7, 2023, Precision BioSciences Inc (DYAI) stock showed promising performances based on the information provided. According to data from CNN Money, the four analysts offering 12-month price forecasts for DYAI had a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00.Nov 29, 2023 · The Precision BioSciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing …

At the core of Precision Biosciences’ groundbreaking research is the ARCUS genome editing technology. This cutting-edge technology possesses unparalleled precision and versatility, enabling scientists to insert, delete, or repair disease-causing DNA in a wide range of genetic disorders. With the potential to revolutionize the field of genetic ...Aug 8, 2023 · ARCUS is a precise and versatile genome editing technology discovered and developed by scientists at Precision BioSciences. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases to insert (knock in), remove (knock out), or repair DNA of living cells and tissues. Real time Precision BioSciences (DTIL) stock price quote, stock graph, ... Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies ...Based on short-term price targets offered by five analysts, the average price target for Precision BioSciences comes to $3.00. The forecasts range from a low of $1.00 to a high of $5.00. The ...Precision BioSciences Announces $50 Million Offering of Common Stock. June 21, 2022 05:25 PM Eastern Daylight Time. DURHAM, N.C.-- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), a ...

On November 7, 2023, Precision BioSciences Inc (NASDAQ:DTIL), an advanced gene editing company, announced its financial results for the third quarter ended September 30, 2023. The company reported ...

Aug 4, 2023 · Precision Biosciences, Inc. Condensed Balance Sheets Data (In thousands, except share amounts) (Unaudited) June 30, 2023: December 31, 2022: Cash and cash equivalents $ 137,794 $ 189,576 Working capital 91,465 139,441 Total assets 181,697 238,169 Total liabilities 147,656 177,736 Total stockholders' equity $ 34,041 $ 60,433 Common stock outstanding

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 24, 2023, Precision BioSciences, Inc. (the "Company") received a letter (the "Nasdaq Staff Deficiency Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last 30 consecutive business days, the closing bid ...Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing …Stock Price Forecast The 4 analysts offering 12-month price forecasts for Precision BioSciences Inc have a median target of 2.75, with a high estimate of 3.00 and a low estimate of 2.00. May 31, 2023 · In a report released today, Justin Zelin from BTIG maintained a Buy rating on Precision BioSciences ( DTIL – Research Report ), with a price target of $6.00. The company’s shares opened today ... Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market Oct 26 Price target decreased by 15% to US$2.60About the Company. Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced a promotion and organizational changes within the Company’s Senior Leadership Team (SLT).. The company announced the promotion of Neil …Insiders have purchased a total of 107,498 DTIL shares in the last 24 months for a total of $168,870.74 bought. Which Precision BioSciences insiders have been selling company stock? The following insiders have sold DTIL shares in the last 24 months: Alan List ($32,602.70), Dario Scimeca ($39,689.22), Derek Jantz ($38,828.94), and Michael ...From Luke: Backing out its $160 million cash balance, Precision is valued at merely $130 million — a cheap valuation for a promising gene-editing company with proprietary tech and a big pharma ...Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is ...DTIL Stock Analysis: Potential +608.72% Increase According to Analysts Forecasts. DTIL stock, the ticker symbol for Precision BioSciences Inc, closed at a price of 0.42 on September 19, 2023. The 5 analysts offering 12-month price forecasts for DTIL have a median target of 3.00, with a high estimate of 4.00 and a low estimate of 1.40.Precision BioSciences Conference Call and Webcast Information. Precision's management team will host a conference call and webcast at 8:30 a.m. ET today, Friday, November 20, 2020 to discuss the collaboration. The dial-in conference call numbers for domestic and international callers are (866) 996-7202 and (270) 215-9609, …

View Precision BioSciences, Inc DTIL investment & stock information. Get the latest Precision BioSciences, Inc DTIL detailed stock quotes, stock data, Real …H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $5.00.The company’s shares opened today at $0 ...

About Precision BioSciences, Inc. ... risks related to ownership of our common stock and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10 ...Precision BioSciences to Present at Upcoming Sidoti Conference. DURHAM, N.C., November 10, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and …Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and ...Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled “ Efficient elimination of MELAS-associated m ...About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control …Specific Internship opportunities for Summer 2024 will be posted in January 2024. Please check back to our careers site for more specific opportunities then. Our …Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Precision BioSciences (DTIL – Research Report) yesterday and set a price target of $1.40.The company’s shares closed ...Precision Biosciences Inc (NASDAQ:DTIL)’s traded shares stood at 0.64 million during the latest session, with the company’s beta value hitting 1.50. At the last check today, the stock’s price was $0.41, to imply a decrease of -3.21% or -$0.01 in intraday trading. The DTIL share’s 52-week ...DURHAM, N.C. -- (BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary …

7 thg 11, 2023 ... DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — Precision BioSciences Inc. (DTIL) on Tuesday reported a loss of $8.1 million in its third quarter.

Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...

Jun 22, 2022 · Additionally, Precision announced a common stock offering yesterday. The company will “sell 35,971,224 shares of its common stock at a price of $1.39 per share.” Nov 20, 2020 · Under the terms of the agreement, Precision will receive an upfront cash payment of $100 million, as well as an equity investment by Lilly of $35 million in Precision's common stock. Precision is also eligible to receive up to $420 million in potential development and commercialization milestones per product, as well as tiered royalties ranging ... Jan 24, 2022 · This free interactive report on Precision BioSciences' balance sheet strength is a great place to start, if you want to investigate the stock further. A Different Perspective. Given that the market gained 5.6% in the last year, Precision BioSciences shareholders might be miffed that they lost 65%. DURHAM, N.C.--(BUSINESS WIRE)--Nov. 30, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel …Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ...Precision BioSciences (DTIL) JonesTrading analyst Soumit Roy reiterated a Buy rating on Precision BioSciences today and set a price target of $4.00. The company’s shares closed last Wednesday at ...Precision BioSciences, Inc. (DTIL) Stock Price, Quote, News & Analysis DTIL Precision BioSciences, Inc. Stock Price & Overview $0.37 0.0099 ( +2.79%) 3:59 …What are individual investors saying about Precision BioSciences? View the latest DTIL social media trends at MarketBeat. Skip to main content. S&P 500 4,594.63 (+0.59%) DOW 36,245.50 (+0.82%) ... Stock Ideas and Recommendations. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the …

JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $4.00.The company’s shares opened today at $0.57. Roy ...Tuesday, April 18, 2023. Precision Biosciences Expects Approximately $158M In Cash And Cash Equivalents As Of March 31, 2023. The Company's Management Also Believes That The Existing Cash And Cash ...H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Precision BioSciences ( DTIL – Research Report) today and set a price target of $17.00. The company’s shares opened today at ...DURHAM, N.C.--(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of …Instagram:https://instagram. best blue chip dividend stocksgood banking appsvideo game stockscalp trading futures Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the ...A high-level overview of Precision BioSciences, Inc. (DTIL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 1964 half dollar how much is it worthbuying tesla stock DTIL stock, the ticker symbol for Precision BioSciences Inc, had a significant increase in its price on November 7, 2023. According to data from CNN Money, the 12-month price forecasts provided by four analysts for DTIL stock have a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00.Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS ® genome editing platform. ARCUS is a highly specific ... premarket screening Nov 14, 2023 · Precision BioSciences (DTIL) Company Description: Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the ... Aug 4, 2023 · Precision Biosciences, Inc. Condensed Balance Sheets Data (In thousands, except share amounts) (Unaudited) June 30, 2023: December 31, 2022: Cash and cash equivalents $ 137,794 $ 189,576 Working capital 91,465 139,441 Total assets 181,697 238,169 Total liabilities 147,656 177,736 Total stockholders' equity $ 34,041 $ 60,433 Common stock outstanding